Literature DB >> 31938170

Mucinous gastric carcinoma: an update of clinicopathologic features and prognostic value from a retrospective study of clinical series.

Yujie Yuan1, Zehong Chen2, Jianhui Chen1, Wensheng Huang1, Jianjun Peng1, Jinning Ye1, Weiling He1, Liang Wang1, Jianbo Xu1, Shirong Cai1, Yulong He1, Wu Song1.   

Abstract

Mucinous gastric carcinoma (MGC) is a specific type of gastric carcinoma, but its clinicopathologic characteristics remains obscured. Our study aimed to explore clinical features and prognostic value of MGC. This retrospective study included a total of 996 patients with primary gastric carcinoma from June 1994 to December 2006. Patients with gastric carcinoma were divided into MGC, other poorly differentiated (PD), and well or moderately differentiated groups. In all, 68 (6.8%) of 996 patients had MGC, with 599 (60.2%) cases for PD. Our study found that MGC had older age, more distant and peritoneal metastasis, but less radical gastrectomy than PD. Furthermore, the overall survival rate of MGC declined compared with PD gastric cancer (22.3% vs. 28.8%, P=0.032). Younger age (≤60 ys), smaller size (≤5 cm), Bormann III type, and lymph node metastasis were linked to poorer prognosis of MGC. However, MGC itself was not an independent prognostic factor of gastric carcinoma. In conclusion, MGC was associated with poorer prognosis than other types of gastric carcinoma but was not an independent predictive factor for survival, which called for further lucubration of this distinctive type of gastric carcinoma. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Clinical pathology; gastric cancer; mucinous carcinoma; prognosis

Year:  2018        PMID: 31938170      PMCID: PMC6958002     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  1 in total

1.  A survival comparison of gastric mucin-producing adenocarcinoma to conventional adenocarcinoma: a SEER database analysis.

Authors:  Qiang Wang; Junbin Zhong; Qing Huang; Zhuanpeng Chen; Jianchang Wei; Fang Wei; Jie Cao
Journal:  BMC Cancer       Date:  2021-10-23       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.